Pharma BD Deal Intelligence
A co-development partnership for enfortumab vedotin that produced Padcev—now generating $3.4B in annual sales after a landmark first-line bladder cancer approval with Keytruda. The deal validated the ADC modality in urothelial cancer and became so valuable Pfizer's $43B Seagen acquisition was partly driven by it.
Astellas / Seattle Genetics (Padcev collaboration): Achieved Stated Rationale (Score: 87/100)
Full analysis, sources & comparables →Seattle Genetics and Astellas announced a clinical trial collaboration with Merck to evaluate enfortumab vedotin in combination with Keytruda in patients with…
Seagen and Astellas win expanded FDA approval for bladder cancer drug Padcev, further establishing the ADC as a cornerstone of urothelial cancer treatment.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Astellas and Seattle Genetics (now Seagen) formed a global collaboration to develop enfortumab vedotin (Padcev), a Nectin-4 targeting ADC for urothelial cancer. The multi-year collaboration involved shared development costs and co-commercialization. Padcev was approved by FDA in 2019 and expanded to first-line use with Keytruda in 2023, generating >$3.4B in sales by 2024. Pfizer acquired Seagen in 2023 inheriting co-commercialization rights.
Astellas / Seattle Genetics (Padcev collaboration): Achieved Stated Rationale (Score: 87/100)
Assessment window: 15yr post-close.
Padcev (enfortumab vedotin, Astellas/Pfizer) received FDA full approval in December 2023 for 1L locally advanced or metastatic urothelial cancer in combination with pembrolizumab based on EV-302 (HR 0.47 for OS versus platinum chemo). The combination is now standard of care. Nectin-4 targeting ADCs (direct MOA class): enfortumab vedotin (Padcev) is first-in-class and solely FDA-approved; disitamab vedotin (RC48, RemeGen/Seagen HER2 ADC with nectin-4 follow-on in development) and BT8009 (Bicycle Therapeutics nectin-4 bicycle toxin conjugate, Phase 2/3) are the principal pipeline threats. Anti-PD-1/PD-L1 monoclonals (combination partner and monotherapy competitor): pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, BMS, FDA-approved as adjuvant in muscle-invasive post-surgery), avelumab (Bavencio, EMD Serono/Pfizer, 1L maintenance), and atezolizumab (Tecentriq, Roche, withdrew 1L indication). FGFR inhibitors (biomarker-selected): erdafitinib (Balversa, J&J) is FDA-approved in FGFR2/3-altered urothelial carcinoma post-platinum. Chemotherapy benchmarks: cisplatin/gemcitabine and carboplatin/gemcitabine were 1L standards pre-EV-302. Astellas reported Padcev global net sales of ~$1.3B FY2023 per 10-K. Commercial framing: Padcev+Keytruda has defined the 1L ceiling; competitive pressure shifts to second-gen nectin-4 ADCs and FGFR-selected segments.
Padcev (enfortumab vedotin, Astellas/Pfizer) plus Keytruda (pembrolizumab, Merck) is under investigation in neoadjuvant/perioperative muscle-invasive bladder cancer (MIBC) in Phase 3 KEYNOTE-B15/EV-304 and KEYNOTE-905/EV-303. No nectin-4 ADC is currently FDA-approved in the neoadjuvant MIBC setting. Neoadjuvant/perioperative immunotherapy (direct MOA competitors in the chemotherapy-ineligible population): nivolumab (Opdivo, BMS) received FDA approval August 2024 for perioperative use in combination with cisplatin/gemcitabine based on CheckMate-901/NIAGARA-adjacent data; durvalumab (Imfinzi, AstraZeneca) plus gemcitabine/cisplatin neoadjuvant followed by adjuvant durvalumab was FDA-approved March 2025 based on NIAGARA (EFS HR 0.68). Adjuvant PD-1 blockade post-cystectomy: nivolumab (Opdivo) is FDA-approved adjuvant per CheckMate-274; pembrolizumab (Keytruda) is approved as adjuvant for high-risk NMIBC post-BCG (Keynote-057). Neoadjuvant chemotherapy (standard of care benchmark): cisplatin/gemcitabine and dose-dense MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) remain guideline-recommended. FGFR-selected: erdafitinib (Balversa, J&J) is not approved in neoadjuvant setting. Commercial framing: Imfinzi+chemo now holds 1L perioperative cisplatin-eligible position; Padcev+Keytruda's opportunity lies in cisplatin-ineligible/chemo-sparing segment, with Phase 3 pCR and EFS data defining head-to-head positioning.
Astellas Pharma Inc. closes co-development of Seagen Inc. for $4.5B, establishing strategic position and initiating integration.
Strategic Fit: 85/100 | Financial Return: 88/100 | Pipeline Outcome: 90/100 | Integration: 80/100 | Deal Difficulty: 55/100. Achieved Stated Rationale overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Seagen Inc. (this deal) | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2009 deals · Astellas Pharma Inc. deals · Oncology deals